We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies. In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
Read MoreHide Full Article
Recursion Pharmaceuticals (RXRX - Free Report) closed the most recent trading day at $6.48, moving -1.52% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.22% for the day. Meanwhile, the Dow experienced a drop of 0.03%, and the technology-dominated Nasdaq saw a decrease of 0.33%.
The the stock of biotechnology company has fallen by 39.47% in the past month, lagging the Medical sector's loss of 0.63% and the S&P 500's loss of 7.48%.
Market participants will be closely following the financial results of Recursion Pharmaceuticals in its upcoming release. The company's upcoming EPS is projected at -$0.44, signifying a 12.82% drop compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $20.15 million, reflecting a 46.12% rise from the equivalent quarter last year.
RXRX's full-year Zacks Consensus Estimates are calling for earnings of -$1.41 per share and revenue of $88.55 million. These results would represent year-over-year changes of +16.57% and +50.5%, respectively.
Any recent changes to analyst estimates for Recursion Pharmaceuticals should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.18% higher. At present, Recursion Pharmaceuticals boasts a Zacks Rank of #3 (Hold).
The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 85, putting it in the top 34% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
Recursion Pharmaceuticals (RXRX - Free Report) closed the most recent trading day at $6.48, moving -1.52% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.22% for the day. Meanwhile, the Dow experienced a drop of 0.03%, and the technology-dominated Nasdaq saw a decrease of 0.33%.
The the stock of biotechnology company has fallen by 39.47% in the past month, lagging the Medical sector's loss of 0.63% and the S&P 500's loss of 7.48%.
Market participants will be closely following the financial results of Recursion Pharmaceuticals in its upcoming release. The company's upcoming EPS is projected at -$0.44, signifying a 12.82% drop compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $20.15 million, reflecting a 46.12% rise from the equivalent quarter last year.
RXRX's full-year Zacks Consensus Estimates are calling for earnings of -$1.41 per share and revenue of $88.55 million. These results would represent year-over-year changes of +16.57% and +50.5%, respectively.
Any recent changes to analyst estimates for Recursion Pharmaceuticals should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.18% higher. At present, Recursion Pharmaceuticals boasts a Zacks Rank of #3 (Hold).
The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 85, putting it in the top 34% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.